Drugs / Probenecid
Probenecid
also known as
Benemid · Benuryl · HC 5006 · NSC-18786 · p-(di-n-propylsulfamyl)-benzoic acid · P-(dipropylsulfamoyl)benzoic acid · PanCytoVir · Probalan · +10 more
Small molecule targets PANX1, SLC22A11, SLC22A6, SLC22A8, TRPV2 via inhibition / activation
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | BENEMID | — | 1951-04-26 | fda.gov ↗ |
Trials 51 · a red edge is where a trial was stopped
1949195019511952195319541955195619571958195919601961196219631964196519661967196819691970197119721973197419751976197719781979198019811982198319841985198619871988198919901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027202820292030203120322033
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 03 trials | ||||||
| Phase 0 | NCT05365451 | Apr 2022 → Jul 2023 | — | Washington State University | Completed | No outcome recorded |
| Phase 0 | NCT03202511 | Jun 2017 → Jul 2018 | — | Indiana University | Completed | No outcome recorded |
| Phase 0 | NCT02243631 | Oct 2014 → Apr 2021 | chondrocalcinosis | VA Office of Research and Development | Completed | No outcome recorded |
| Phase 128 trials | ||||||
| Phase 1 | NCT07661108 | Jun → Oct 2026 expected | — | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 1 | NCT07092813 | Apr → Oct 2026 expected | — | Iterum Therapeutics, International Limited | Recruiting | No outcome recorded |
| Phase 1 | NCT07160738 | Sep → Nov 2025 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT06647810 | Nov → Dec 2024 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT06025318 | Sep 2024 | — | TrippBio, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT06025344 | Sep 2024 | — | TrippBio, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT06416800 | Jun 2024 → Jan 2025 | — | Incyte Corporation | Completed | No outcome recorded |
| Phase 1 | NCT05954624 | Jul → Nov 2023 | — | Guangdong Raynovent Biotech Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT05881811 | Mar → Apr 2023 | postherpetic neuralgia | Haisco Pharmaceutical Group Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05618314 | Oct 2022 → Jun 2024 | impaired renal function disease | Atea Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05497674 | Feb → Jul 2022 | type 2 diabetes mellitus | Sunshine Lake Pharma Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05280054 | Dec 2021 → Sep 2022 | — | VistaGen Therapeutics, Inc. | Unknown | No outcome recorded |
| Phase 1 | NCT05045313 | Oct → Dec 2021 | — | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04700787 | Apr 2021 → Mar 2022 | acute pyelonephritis, infectious peritonitis | Iterum Therapeutics, International Limited | Withdrawn | No outcome recorded |
| Phase 1 | NCT04218357 | Dec 2020 → May 2023 | alcohol-related disorders | Brown University | Completed | No outcome recorded |
| Phase 1 | NCT03937258 | May → Jul 2019 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT03801746 | Jul → Aug 2018 | — | Akebia Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT03466567 | Mar → Jul 2018 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT03307252 | Oct 2017 → May 2018 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT03296800 | Sep → Dec 2017 | type 2 diabetes mellitus | Theracos | Completed | No outcome recorded |
| Phase 1 | NCT03105986 | Apr → Jun 2017 | — | Janssen-Cilag International NV | Completed | No outcome recorded |
| Phase 1 | NCT03138759 | Feb → Mar 2017 | — | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 1 | NCT01937026 | Sep → Nov 2013 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01634100 | Jun → Aug 2012 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT01428284 | Aug → Oct 2011 | — | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | No outcome recorded |
| Phase 1 | NCT00842400 | Feb → Mar 2009 | obesity disorder | VIVUS LLC | Completed | No outcome recorded |
| Phase 1 | NCT00439530 | Nov 2006 → Apr 2007 | avian influenza | Mahidol University | Completed | No outcome recorded |
| Phase 1 | NCT00024245 | May 2001 → Apr 2003 | cancer of unknown primary site | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05082909 | Dec 2021 → Jul 2022 | bacterial infectious disease | Imperial College London | Completed | No outcome recorded |
| Phase 1/2 | NCT01322009 | Mar 2011 → Dec 2013 | traumatic brain injury | University of Pittsburgh | Completed | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT07118618 | Mar 2026 → Dec 2030 expected | alcohol-related disorders | Brown University | Recruiting | No outcome recorded |
| Phase 2 | NCT07318870 | Jan 2026 → Feb 2029 expected | focal epilepsy | Fondation Ophtalmologique Adolphe de Rothschild | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05190744 | Sep 2022 → Dec 2025 | autosomal dominant polycystic kidney disease, nephrogenic diabetes insipidus | Mayo Clinic | Completed | No outcome recorded |
| Phase 2 | NCT05442983 | Jul → Sep 2022 | COVID-19 | TrippBio, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01814319 | Mar 2013 → Jun 2015 | systolic heart failure | University of Cincinnati | Completed | No outcome recorded |
| Phase 2 | NCT00288158 | Sep 2008 → Jan 2011 | hypertensive disorder, obesity disorder | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT05903859 | Jan 2024 → May 2027 expected | male infertility | University of Miami | Recruiting | No outcome recorded |
| Phase 3 | NCT05584657 | Oct 2022 → Nov 2023 | cystitis, urinary tract infection | Iterum Therapeutics, International Limited | Completed | No outcome recorded |
| Phase 3 | NCT01320722 | Mar 2011 → May 2015 | hypertensive disorder, impaired renal function disease, obesity disorder | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 3 | NCT00323219 | Jan 2004 → Dec 2012 | cellulitis | University of British Columbia | Completed | No outcome recorded |
| Phase 44 trials | ||||||
| Phase 4 | NCT03965351 | Mar 2017 → Jun 2020 | Fontan-associated liver disease | Children's Hospital Medical Center, Cincinnati | Completed | No outcome recorded |
| Phase 4 | NCT01907373 | Aug → Sep 2009 | — | Central South University | Completed | No outcome recorded |
| Phase 4 | NCT00610532 | Mar 2006 → Jun 2011 | epilepsy | Jim McAuley | Terminated | No outcome recorded |
| Phase 4 | NCT00304434 | Feb 2005 → Feb 2007 | influenza | US Department of Veterans Affairs | Completed | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT00690014 | Aug 2006 → Apr 2007 | kidney disorder | University of Maryland, Baltimore | Completed | No outcome recorded |
| — | NCT00000706 | ? → Dec 1988 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| — | NCT00000670 | ? → Jul 1989 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT04682834 | — | acute pyelonephritis | Iterum Therapeutics, International Limited | No longer available | No outcome recorded |
Also used as a comparator or background therapy in 13 trials
Evidence & citations 26 cited values
Every value below carries the sentence it was read from. 67 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Probenecid | “The medical intervention consists of intravenous dexamethasone (10 mg if bodyweight \< 70 kilograms, 20 mg if bodyweight \> 70 kilograms), intravenous cefazolin 2 grams,...” NCT04998513 ↗63“Objective: To compare 400 mg of oral moxifloxacin (Oral Group) once daily to 2 grams of IV cefazolin and 1 gram of oral probenecid once daily (IV group) for the treatment of...” NCT00323219 ↗ “The following day, patients will receive a single dose of 500 mg of sulopenem etzadroxil and 500 mg of probenecid given orally as a bilayer tablet.” NCT04700787 ↗ “Subjects will receive a single oral dose of probenecid oral suspension (100 mg/mL) under fed and fasted conditions.” NCT06025318 ↗ “Probenecid (PB)” NCT05190744 ↗ |
| Known as | Benemid | ChEMBL registry synonym — accepted as the source's own label CHEMBL897 ↗ |
| Known as | Benuryl | ChEMBL registry synonym — accepted as the source's own label CHEMBL897 ↗ |
| Known as | HC 5006 | ChEMBL registry synonym — accepted as the source's own label CHEMBL897 ↗ |
| Known as | NSC-18786 | ChEMBL registry synonym — accepted as the source's own label CHEMBL897 ↗ |
| Known as | p-(di-n-propylsulfamyl)-benzoic acid | “Probenecid, p-(di-n-propylsulfamyl)-benzoic acid, is a drug used clinically to treat hyperuricemia and gout due to its activity as an inhibitor of the kidneys' organic anion...” PMID 31535696 ↗ Jan 2019 |
| Known as | P-(dipropylsulfamoyl)benzoic acid | ChEMBL registry synonym — accepted as the source's own label CHEMBL897 ↗ |
| Known as | PanCytoVir | “PanCytoVir™ (probenecid)” NCT05442983 ↗ |
| Known as | Probalan | ChEMBL registry synonym — accepted as the source's own label CHEMBL897 ↗ |
| Known as | Probampicin | ChEMBL registry synonym — accepted as the source's own label CHEMBL897 ↗ |
| Known as | Probecid | ChEMBL registry synonym — accepted as the source's own label CHEMBL897 ↗ |
| Known as | Probenate | ChEMBL registry synonym — accepted as the source's own label CHEMBL897 ↗ |
| Known as | Probenecid component of col- | ChEMBL registry synonym — accepted as the source's own label CHEMBL897 ↗ |
| Known as | Probenecid component of colbenemid | ChEMBL registry synonym — accepted as the source's own label CHEMBL897 ↗ |
| Known as | Probenecid component of orlynvah | ChEMBL registry synonym — accepted as the source's own label CHEMBL897 ↗ |
| Known as | Probenecid component of probampacin | ChEMBL registry synonym — accepted as the source's own label CHEMBL897 ↗ |
| Known as | Probenecid component of proben-c | ChEMBL registry synonym — accepted as the source's own label CHEMBL897 ↗ |
| Known as | Probenecide | ChEMBL registry synonym — accepted as the source's own label CHEMBL897 ↗ |
| Known as | Probenecidum | ChEMBL registry synonym — accepted as the source's own label CHEMBL897 ↗ |
| Action | Inhibit | “probenecid effectively inhibited the transport of PAH, Ro 64-0802, and amoxicillin via hOAT1.” PMID 11744606 ↗ Jan 20023“Solute carrier family 22 member 11 inhibitor” CHEMBL897 ↗ “Solute carrier family 22 member 6 inhibitor” CHEMBL897 ↗ “Solute carrier family 22 member 8 inhibitor” CHEMBL897 ↗ |
| Modality | Small molecule | — CHEMBL897 ↗ |
| Route | Oral | “patient starts taking probenecid by mouth every 8 hours” NCT00000670 ↗ |
| Target | PANX1 | “Probenecid also inhibits pannexin1 channels that are involved in purinergic neurotransmission and inflammation” PMID 31535696 ↗ Jan 2019 |
| Target | SLC22A11 | “Solute carrier family 22 member 11 inhibitor” CHEMBL897 ↗ |
| Target | SLC22A6 | “Solute carrier family 22 member 6 inhibitor” CHEMBL897 ↗ |
| Target | SLC22A8 | “Solute carrier family 22 member 8 inhibitor” CHEMBL897 ↗ |